![Victor W. van Beusechem](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Victor W. van Beusechem
Direttore Tecnico/Scientifico/R&S presso ORCA Therapeutics BV
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Kees Groen | M | 63 |
ORCA Therapeutics BV
![]() ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands. | - |
Mark R.L. Krul | M | - |
ORCA Therapeutics BV
![]() ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands. | - |
Jan Hendrik Egberts | M | 65 |
ORCA Therapeutics BV
![]() ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands. | - |
Ramon Alemany | M | - |
ORCA Therapeutics BV
![]() ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands. | - |
Wenliang Dong | M | - |
ORCA Therapeutics BV
![]() ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Onno van de Stolpe | M | 64 |
Introgene BV
| 1 anni |
Abraham Bout | M | - |
Janssen Vaccines & Prevention BV
![]() Janssen Vaccines & Prevention BV Pharmaceuticals: MajorHealth Technology Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands. | 14 anni |
Menzo Havenga | M | - |
Introgene BV
| 7 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Paesi Bassi | 8 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Victor W. van Beusechem
- Contatti personali